Clinical Trial Update: Study Evaluating Multiple Ascending Dose in Schizophrenia Patients [Phase 1]

View source ↗

Summary

Phase 1 multiple ascending dose study in schizophrenia patients was terminated; sponsor Wyeth is now part of Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Healthy | Phase 1 | Status: TERMINATED